An international consortium of 9 research groups, consisting of five academic groups, two commercial partners and one pharmaceutical partner. The consortium consists of groups from the Leiden University Medical Center, University of Leiden, University of Antwerp, Sorbonne University, University of Vienna, University of Copenhagen, Mitologics, FFUND and Janssen Pharmaceutica. Through this combined effort the RespiriTB & RespiriNTM consortium aims to develop novel antibiotics that will shorten the treatment time of mycobacterial infection and circumvent the rise of drug-resistant bacteria that form a major threat to human health and kill > 1.5 million people each year.
RespiriTB and RespiriNTM are supported by the Innovative Medicines Initiative (IMI) and Janssen Pharmaceutica. IMI is the world's biggest public-private partnership in the life sciences that facilitate collaboration between the European Commission and industry partners. IMI aims to the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and SMEs, patient organisations, and medicines regulators.
The RespiriTB and RespiriNTM project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853903 and No 853932. This Joined Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.